TG Therapeutics' Briumvi has shown strong revenue growth, with $310 million in FY24, and is expected to reach $540 million in ...

In a report released today, Alec Stranahan from Bank of America Securities maintained a Sell rating on TG Therapeutics (TGTX – Research ...

Learn more about whether Neurocrine Biosciences, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ ...

Shares of TG Therapeutics, Inc. TGTX have rallied 29.5% in the past three months against the industry’s decline of 11.2%. The ...

TG Therapeutics (TGTX) stock spikes as Roche (RHHBY) fails in a Phase 3 trial for a high dose version of its multiple sclerosis therapy Ocrevus. Read more here.

This leads investors to also remain optimistic about rising dividends in the future. TG Therapeutics has a better P/E ratio of 244.73 than the aggregate P/E ratio of 41.86 of the Biotechnology ...

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a ...

TG Therapeutics, Inc. NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 ...

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing ...

Shares of TG Therapeutics, Inc. TGTX have rallied 29.5% in the past three months against the industry’s decline of 11.2%. The company’s sole marketed drug Briumvi (ublituximab-xiiy ...